Xynomic Pharmaceuticals
PrivateLast Round
M&A
May 15, 2019
Est. Valuation
$350M
Total Funding Raised
$26.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Xynomic Pharmaceuticals operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in August 2018.
Xynomic Pharmaceuticals is a biopharmaceutical company that focuses on in-licensing, developing, and commercializing oncology drug candidates.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xynomic Pharmaceuticals Comparables
Compare Xynomic Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 成都赜灵生物医药科技有限公司 | 83% | |
| EOC Pharma | 80% | |
| HUYA Bioscience International | 80% |
For institutional investors. Book with your work email.
Xynomic Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | May 15, 2019 | ||||
| Series B | Aug 1, 2018 | ||||
| Debt | May 1, 2018 | ||||
| Debt | Apr 1, 2018 | ||||
| Debt | Aug 15, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Xynomic Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Northern Light Venture Capital | Series B |
| Jingxu Venture Capital | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 58% MoM, reaching 2.1K.
- May 15, 2026
Monthly visitors grew 49% MoM, reaching 1.4K.
For institutional investors. Book with your work email.
Xynomic Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xynomic Pharmaceuticals's valuation, stock price, and market status.
Is Xynomic Pharmaceuticals a public or private company?
Xynomic Pharmaceuticals is a private company.
What is the current stock price of Xynomic Pharmaceuticals?
Xynomic Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Xynomic Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xynomic Pharmaceuticals worth (valuation)?
Xynomic Pharmaceuticals's valuation is estimated at $350.0M based on funding round data.
Can I buy Xynomic Pharmaceuticals stock?
Xynomic Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xynomic Pharmaceuticals's last funding round?
Xynomic Pharmaceuticals's most recent funding round was M&A on May 15, 2019.
Who are the main investors in Xynomic Pharmaceuticals?
Key investors in Xynomic Pharmaceuticals include Northern Light Venture Capital.
Will Xynomic Pharmaceuticals IPO soon?
No public IPO plans have been announced for Xynomic Pharmaceuticals.
How can I track Xynomic Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Xynomic Pharmaceuticals's shares on secondary markets.